Pathfinder Therapeutics Inc. said Thursday it had closed on $5.2 million worth of financing led by venture capitalists Hatteras Venture Partners of Research Triangle Park, N.C.
The other investors included Vanderbilt University, Clayton & Associates, Nashville Capital Network and Lumira, a venture capital firm with offices in the U.S. and Canada.
Also, Richard Molloy of Florida Gulfshore Capital and Hatteras Venture Partners' Clay Thorp and Bob Morff have joined the company's board. Morff is interim CEO.
The money will be used to launch Pathfinder's liver surgery medical devices, both of which have received U.S. Food and Drug Administration approval.
Business Briefs: BioMimetic raises cash balance
End of IPO dry spell may be in sight
Commercial Financing is Available for the Right Buyer and the Right Property
